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Abstract
Background: Due to widespread PSA testing incidence rates of localized prostate cancer increase but curative treatment
is often not required. Overtreatment imposes a substantial economic burden on health care systems. We compared the
direct medical costs of conservative management and radical therapy for the management of early-stage prostate cancer
in routine care.
Methods: An observational study design is chosen based on claims data of a German statutory health insurance fund for
the years 2008–2011. Three hundred fifty-three age-matched men diagnosed with prostate cancer and treated
with conservative management and radical prostatectomy, are included. Individuals with diagnoses of metastases
or treatment of advanced prostate cancer are excluded.
In an excess cost approach direct medical costs are considered from an insured community perspective for in- and
outpatient care, pharmaceuticals, physiotherapy, and assistive technologies. Generalized linear models adjust for
comorbidity by Charlson comorbidity score and recycled predictions method calculates per capita costs per
treatment strategy.
Results: After follow-up of 2.5 years per capita costs of conservative management are €6611 lower than costs of
prostatectomy ([−9734;−3547], p < 0.0001). Complications increase costs of assistive technologies by 30% (p = 0.0182),
but do not influence any other costs. Results are robust to cost outliers and incidence of prostate cancer diagnosis. The
short time horizon does not allow assessing long-term consequences of conservative management.
Conclusions: At a time horizon of 2.5 years, conservative management is preferable to radical prostatectomy in terms
of costs. Claims data analysis is limited in the selection of comparable treatment groups, as clinical information is scarce
and bias due to non-randomization can only be partly mitigated by matching and confounder adjustment.
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Background
Prostate cancer (PCa) is the second most common
cancer in men worldwide and the most common in
Germany [1, 2]. Annual health care spending due to PCa
is substantial and accounts for €5.43 billion in the
European Union (EU). Germany exhibits the highest
PCa-related health care costs per person in the EU,
mostly due to inpatient expenditures [3]. Due to wide-
spread prostate specific antigen (PSA) testing incidence
rates and health care spending will increase significantly
in the EU in the future. Detected tumors are often local-
ized, clinically insignificant cancers, though. Data sug-
gest that many men with localized PCa do not benefit
from curative treatment with radical prostatectomy (RP)
in terms of survival because tumor progression is so
slow that no treatment is required [4].
The conservative management (CM) strategies active
surveillance (AS) and watchful waiting (WW) are pro-
posed in this context for the treatment of localized PCa
to reduce overtreatment and subsequent complications
such as erectile dysfunction (ED) and urinary incontinence
(IC). Under AS regular biopsies, PSA tests, and digital rec-
tal examinations are performed to initiate curative treat-
ment if tumor progression occurs. If life expectancy is less
than 10 years or comorbidity does not allow any other
form of PCa-treatment WW is recommended. This strat-
egy has no standardized follow-up scheme; symptom-
oriented, palliative therapy is initiated if disease progresses
[5]. A CM-strategy may save health care costs of unneces-
sary curative therapy and treatment of its adverse effects.
Current economic studies suggest that, while health out-
come in terms of survival and quality of life is similar for
CM and curative treatment, CM is a cost-saving strategy
over the first 5 to 10 years of treatment [6–12]. Most stu-
dies base cost analysis on US reimbursement values,
which are often not representative for European health
care [13]. To guide treatment decisions in a European
health care context observational studies are needed dis-
playing routine care and actual health care spending on
CM compared to RP.
In a German health care context, claims data of statu-
tory health insurance (SHI) funds are a valuable evidence
source as medical care, resource use, and costs are docu-
mented in detail and over a long period of time for a large
cohort of patients. About 85% of the German population
is insured within the social security system of SHI, which
is characterized by pay-as-you-go financing and income-
dependent insurance contributions. The remaining 15%
are covered by private insurance. SHI covers inpatient and
outpatient care, pharmaceuticals, physiotherapy, and as-
sistive technologies. Co-payments of patients are compul-
sory, especially for pharmaceuticals and medical aids [14].
It is the objective of this paper to analyze claims data
of a German AOK SHI fund regarding costs of CM
compared to RP in an age-matched and comorbidity-
adjusted cohort of men with early-stage PCa.
Methods
Data
AOK Baden-Württemberg is the largest SHI fund in
the south-western German federal state of Baden-
Württemberg with about 3.8 million insured indivi-
duals. About 25% of the insured population is retired
and over 65 years. Data on all claims incurred at AOK
between 2008 and 2011 were provided on a patient
level. Co-payments to medical services covered by SHI
are included in the dataset, whereas patients’ out-of-
pocket payments for other services are not. German data
protection laws were considered during extraction and
analysis of data and AOK approved of the intended use of
the data. An ethics committee was consulted regarding
this study; ethics approval is not necessary as identifica-
tion of individuals is not possible in the dataset.
Study design and cohort selection
A prospective, longitudinal study design is chosen,
where a cohort of men diagnosed with early-stage PCa is
followed from the point of treatment initiation.
The study period is January 1st 2008 to December
31st 2011 and is divided into three sections (Fig. 1):
1) The 6-month pre-observation period (January 1st
2008 to June 30th 2008) is created as a basis for the
calculation of the Charlson comorbidity score (CCS),
in order to allow for comorbidity adjustment of costs.
2) In the 12-month observation period from July 1st
2008 to June 30th 2009 PCa-cases are identified
and categorized into the two treatment-groups CM
and RP.
3) Both treatment groups are followed-up for a period
of exactly 2.5 years (follow-up period). In case of RP,
follow-up time starts individually for each person
after the date of the initial prostatectomy procedure
and follows each man for 2.5 years on an individual
basis. Men under CM, on the other hand, are followed
for a fixed period from July 1st 2009 to December 31st
2011. The reason for this is, firstly, that the starting
point of CM cannot be established in the cohort; an
artificial starting point has to be created, which is the
beginning of the observation period (July 1st 2008).
Secondly, follow-up is not intended to start with the
onset of CM. This is due to the cohort selection,
where men under CM have to be surveyed for at
least 12 months (the observation period) to be
included in the cohort; men dying in this period are
not considered for analysis. In the RP- group a
single event in the observation period determines
inclusion in the cohort, which in turn possibly
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includes men dying in this period. To account for
this bias, follow-up of AS is offset by 12 months.
The baseline dataset includes all men with an ICD-10
diagnosis ‘C61–Malignant neoplasm of prostate’ in the
12-month observation period. PCa diagnosis is validated
by only considering men with at least one inpatient or at
least two outpatient diagnostic codes (N = 25,367). After
exclusion of 71 individuals not constantly insured at AOK
Baden-Württemberg in the study period (defined by the
coding of ‘transition to another insurance fund’ in the
claims data) and three individuals with female gender cod-
ing, the baseline data set includes 25,293 individuals
(Fig. 2, Additional file 1: Table S1 and Table S2).
CM is defined by outpatient procedure codes of at least
two PSA tests and one prostate biopsy during the observa-
tion period, including AS- and WW-patients [15]. Add-
itionally, patients undergoing any form of PCa-specific
therapy other than CM are excluded to avoid misclassifica-
tion of patients due for curative treatment as CM cases. In
the follow-up period, men in the CM-group do not have to
be surveyed as defined in the observation period; they may
move on to any other form of PCa-specific therapy.
RP is defined by procedure codes on open, laparoscopic,
or robotic-assisted radical prostatectomy. Patients with
metastatic disease or any other cancer disease coding are
excluded. Exclusion of any PCa-specific therapy other than
RP is not necessary, as these are not found in the RP-
group.
Considering the inclusion criteria the cohort consists of
124 and 910 individuals under CM and RP, respectively.
Statistical analysis
To control for age as a confounder of cost differences,
treatment groups are matched by +/− 2 years. After
matching in a ratio of 1:2 the CM-group includes 107
individuals, and the RP-group includes 214 individuals.
Patients’ age and CCS as well as prevalence of ED, IC,
and benign prostate hyperplasia (BPH) are calculated at
baseline before and after matching. For calculation of
CCS the comorbidity-group ‘cancer’ is set 0, because
diseases other than PCa are of interest for adjustment.
We use an excess cost approach to display cost differ-
ences between treatment strategies for inpatient and out-
patient care, pharmaceuticals, physiotherapy, and assistive
technologies. All direct medical costs and co-payments
are considered that are relevant for the perspective of the
SHI scheme insured community (§ 35b (1) SGBV) [16].
Comorbidity-adjusted cost differences between treatment
groups are estimated by a generalized linear model (GLM)
with a gamma distribution and log link to account for the
typically skewed distribution of cost data. If less than 10%
of individuals in the cohort have zero costs a small
amount of 1 Euro (€) is assigned to include them in the
analysis [17]. If individuals with zero costs account for
more than 10% of the cohort a two-part model is used: at
first, the probability of health care expenditure is pre-
dicted with a logistic regression model. Secondly, costs are
estimated by a GLM, as described above, conditional for
nonzero costs. To derive unconditional costs the probabi-
lity of expenditure is multiplied by the predicted condi-
tional costs [18]. Recycled predictions are used to estimate
per capita costs per treatment strategy in addition to per-
centage values of differences reported by the GLM [19].
All costs are rounded to the nearest € to present only full
€ amounts with no cent values; discounting is not consi-
dered due to the short study period.
Ninety-five percent confidence intervals (CI) are calcu-
lated for costs via a non-parametric bootstrap approach
based on 1000 replications. Difference in costs is tested
Fig. 1 Study timeline
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via bootstrap hypothesis testing and p-values less or
equal than 0.05 are considered statistically significant
[20]. The CCS is included in the regression models as a
continuous variable [21, 22]. To additionally estimate
the influence of ED and IC on treatment costs, compli-
cation is included in the regression models as a binary
variable. Extended models with an interaction between
treatment strategy and CCS do not improve model fit.
In a sensitivity analysis we include only incident PCa
cases, with no C61 code in the pre-observation period–as-
suming that CM is initiated with the first PCa-diagnosis–to
estimate the influence of the cohort selection on outcomes.
Statistical analyses are performed with the software
package SAS, version 9.3.
Results
Descriptive analysis
Mean age at baseline after matching is 69 years (STD
6.80) in the RP-group and 70 years (STD 7.13) in the CM-
group, with a mean CCS of 0.11 and 0.19, respectively.
ED, IC and BPH are most prevalent in the RP-group at
baseline (Table 1).
Cost analysis
Figure 3 shows unadjusted per capita costs for the two
treatment strategies grouped by inpatient and outpatient
treatment, pharmaceuticals, physiotherapy, and assistive
technologies. RP has overall higher mean costs, when
compared to CM. Comorbidity-adjusted analysis confirms
this (RP: €18,544, CM: €11,933).
Comparison of adjusted costs (Table 2) displays that
CM has significantly lower mean inpatient (€−5845
Table 1 Baseline characteristics before and after matching
Before matching After matching
RP CM RP CM
Total (n) 910 124 214 107
Age (mean, STD) 66 (6.64) 70 (8.31) 69 (6.80) 70 (7.13)
CCS (mean, STD) 0.13 (0.71) 0.19 (0.62) 0.11 (0.63) 0.19 (0.63)
ED (n, prop.) 79 (0.09) 5 (0.04) 24 (0.11) 5 (0.05)
IC (n, prop.) 18 (0.02) 5 (0.04) 10 (0.05) 3 (0.03)
BPH (n, prop.) 511 (0.56) 83 (0.67) 164 (0.77) 73 (0.68)
CM conservative management, n number, prop. proportion, RP radical
prostatectomy, STD standard deviation
Active surveillance
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Fig. 2 Cohort selection
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[−7632;−3895], p < 0.0001) and outpatient costs (€−961
[−1622;−361], p = 0.002) as well as costs for assistive
technologies (€−141 [−230;−50], p = 0.006) than RP.
Overall, total incremental costs of CM are significantly
lower compared to RP (€−6611 [−9734;−3547], p < 0.0001)
(Fig. 4). Inclusion of complication as a binary variable
in the regression models does not change cost differ-
ences between treatment strategies. Concerning total
costs there is no significant cost difference found be-
tween individuals with and without complications. In
case of assistive technologies a significant 30% increase
in costs for individuals with complications is estimated
(p = 0.018).
For the analysis of inpatient, outpatient, pharma-
ceutical, physiotherapy, and assistive technology costs
two-part models are used, as more than 10% of indi-
viduals have zero costs respectively. Total costs are
analyzed in a one-part model, as no individuals have
zero costs.
Sensitivity analysis
Analysis of costs is repeated including incident PCa-cases
only, which comprised of an age-matched cohort of 320
men (CM: 64, RP: 128). Cost analysis reveals that mean
comorbidity-adjusted total costs of CM increase by €1496
to €13,430 in total compared to base case. Outpatient
costs of CM also increase compared to base case from
€2332 to €2499. Overall, CM is still significantly less costly
than RP (€−5263 [−9530;−1164], p = 0.016) in the incident
cohort.
Discussion
This is, to our knowledge, the first observational study
comparing costs of CM to RP in a European health care
context. Use of claims data allows picturing actual treat-
ment practice of early-stage PCa in Germany. Cost ana-
lysis is based on exact and detailed cost information on
different health care sectors which is representative for
the costs incurred by the SHI scheme insured community,
contrary to many clinical trials. Compared to modeling
studies assumptions on resource use and reimbursement
practice are not required.
CM is overall significantly less costly than RP which
mainly originates in the significant difference of inpatient
costs, presumably due to the high costs of the initial RP-
surgery. Compared to RP outpatient care is also less costly
under CM in the period of 2.5 years follow-up, despite
that the main costs of CM arise in outpatient care. This is
due to different cost patterns, where surgery incurs high
initial outpatient costs (e.g. for post-operative care after
RP) while costs of surveillance, especially AS, are more
equally distributed over time [6–9]. The sensitivity
Fig. 3 Costs per capita (€)–unadjusted
Table 2 Difference in costs (€) between CM and RP-adjusted
CM–RP
Mean 95% CI P-value
Inpatient −5845 −7632 to −3895 <0.0001
Outpatient −961 −1622 to −361 0.002
Pharmaceuticals 587 −556 to 1718 0.274
Physiotherapy −58 −214 to 114 0.460
Assistive technologies −141 −230 to −50 0.006
Total costs −6611 −9734 to −3547 <0.0001
CM conservative management, RP radical prostatectomy
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analysis with incident PCa-cases–which assumes that CM
is initiated with the first PCa-diagnosis–shows that out-
patient costs increase compared to base case which may
lead to the conclusion that CM-costs are comparably
higher in the initial phase.
In the base case analysis pharmaceutical costs are
higher under CM compared to RP, not significantly
though; this may be explained by pharmaceutical treat-
ment of BPH in the CM-group which is not necessary in
the RP-group.
Published cost studies with a European health care con-
text comparing CM and RP report similar cost differences
to our study. Andersson et al. [23] report €6123 lower
costs of WW compared to RP over a follow-up of 12 years
based on data from the SPCG-4 clinical trial [23]. In a life-
time modeling study, Koerber et al. [7] estimate that
under AS compared to RP costs are reduced by about
€6900 [7]. Both in the published studies and in our study,
the cost difference between CM and RP is almost exclu-
sively due to the costs of the initial RP-surgery.
Several US-based observational and modeling studies
show that CM is the least costly strategy over the whole
study duration, consistent with the results presented
here [6, 10, 12, 8, 24]. Only the study by Perlroth et al.
[11] reports that from year 2 of the study on costs of
CM become equal to costs of RP [11]. Perlroth et al. do
not state unit costs of the surveillance scheme; however,
other US-based studies show that the unit costs of pros-
tate biopsy ($605–$1102) alone are considerably higher in
the US health-care context than unit costs of the whole
surveillance scheme (PSA testing and biopsy) in Germany
(€44) [6, 8, 24]. Because of the limited study duration only
short-term costs can be assessed in this study; as pub-
lished studies do, however, suggest that cost differences
between CM and curative treatment, especially RP, arise
in the first years after treatment, the results of this study
may support the conclusion that costs of CM do not arise
to costs of RP in a lifetime perspective [25].
Our study has some limitations. Regarding cohort
selection, there is no information on tumor stage or
Gleason score included in claims data, which might
allow clinical classification of PCa. To account for this
limitation we define early-stage PCa as absence of both
diagnoses of metastases and treatment associated with
recurrence or advanced tumor progression. Inclusion in
the CM-group cannot be based on clinical criteria or
specific procedure codes and therefore a distinction
between WW- and AS-patients is not possible. Seven
Percent of men under CM receive at least one biopsy
during follow-up which suggests that these are under







Fig. 4 Histogram total costs
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AS, while the remaining men may be under WW. The
cohort’s life expectancy, however, is with a mean age of
70 years at baseline greater than 10 years and men are–
according to treatment guideline–not eligible to WW.
Patients might actually be under AS, but are not sur-
veyed by regular biopsies according to guideline. This
might be due to current studies on adverse effects of ser-
ial biopsies on erectile function and infectious complica-
tions [26, 27]. Furthermore, randomization of individuals
into treatment groups is not possible as in any other ob-
servational study; estimated differences between groups
might be attributed to unequal distribution of confound-
ing variables. This bias is reduced by matching and re-
gression analysis only to a certain degree, because the
number of variables available for confounder adjustment
is limited in our data set. Also, descriptive analysis of pa-
tient characteristics after matching shows that men in
the CM-group have more co-morbidities than in the RP-
group (CCS 0.19 vs. 0.11), which is adjusted for in re-
gression analysis. Men in the RP-group, on the other
hand, show higher rates of BPH than men under CM,
which might be explained by the treatment itself; radical
prostatectomy is a treatment for BPH, too.
Regarding the study design, a 12-month observation
period is chosen which excludes CM-patients who receive
curative therapy in this period. The probability for curative
treatment in the first year of CM is, however, low (<5%)
[28]. Also it is necessary in this study to allow enough time
to confirm the CM-strategy and exclude patients who are
waiting for curative treatment, which is done 6 months
after the initial PCa-diagnosis latest [29]. This study might
underestimate costs of the CM-strategy slightly by the
exclusion of cases with curative treatment in the first year.
Alternative treatment options like radiotherapy were ex-
cluded from the study due to the availability of claims data
for a limited duration. Complications after radiotherapy,
usually develop after a longer period than analyzed here,
which might underestimate the costs of radiotherapy.
Regarding cost analysis, calculation of costs for single
procedures is not conducted in this study as case num-
bers are too small to be representative. CCS is not able
to adjust for comorbidities with high outpatient and
pharmaceutical costs as the score was developed to
assess inpatient mortality. We do not account for de-
pendency of data due to matching by using conditional
regression analysis. Dependency of data is very low as
we only match for age; also no longitudinal analysis of
single individuals is intended.
Generalizability of results to the general population
is limited as claims data cannot report out-of-pocket-
payments. Also, due to the excess cost approach absolute
costs do not reflect PCa treatment specific costs and no
conclusion can be inferred on the costs of RP and CM
from this study.
Conclusions
Overall, our analysis indicates that initial treatment costs
as well as short-term follow-up costs of CM based on
claims data of a German SHI fund are significantly lower
than the costs of curative therapy with RP for early-stage
PCa–predominantly due to the high initial costs of the
surgery. Treatment of complications following initial
therapy has a very small impact on costs. These results
must be interpreted in light of the limitations regarding
cohort selection in claims data.
Further research is necessary to analyze costs of CM
compared to curative treatment over a longer time horizon
than reported in this study including costs of long-term
complications and end-of-life care.
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